keyword
MENU ▼
Read by QxMD icon Read
search

Cancer associated thrombosis

keyword
https://www.readbyqxmd.com/read/29325825/-thromboembolic-disease-in-pediatric-oncology
#1
A Theron, C Biron-Andreani, S Haouy, L Saumet, M Saguintah, E Jeziorski, N Sirvent
The survival rate of children with cancer is now close to 80 %, as a result of continuous improvement in diagnostic and treatment procedures. Prevention and treatment of treatment-associated complications is now a major challenge. Thromboembolic venous disease, due to multifactorial pathogenesis, is a frequent complication (up to 40 % asymptomatic thrombosis in children with cancer), responsible for significant morbidity. Predominantly in children with acute lymphoblastic leukemia, lymphoma, or sarcoma, thromboembolic disease justifies primary prophylaxis in certain populations at risk, whether genetic or environmental...
January 8, 2018: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/29325226/citrullinated-histone-h3-a-biomarker-of-neutrophil-extracellular-trap-formation-predicts-the-risk-of-venous-thromboembolism-in-cancer-patients
#2
Lisa-Marie Mauracher, Florian Posch, Kimberly Martinod, Ella Grilz, Thomas Däullary, Lena Hell, Christine Brostjan, Christoph Zielinski, Cihan Ay, Denisa D Wagner, Ingrid Pabinger, Johannes Thaler
BACKGROUND: Neutrophil extracellular traps (NETs) are decondensed chromatin fibers which might play a role in the prothrombotic state of cancer patients. OBJECTIVES: Here we investigated whether citrullinated histone H3 (H3Cit), a biomarker for NET formation, cell-free DNA (cfDNA), and nucleosomes predict venous thromboembolism (VTE) in cancer patients. PATIENTS/METHODS: Nine-hundred-forty-six patients with newly-diagnosed cancer or progression after remission were enrolled in this prospective observational cohort study...
January 11, 2018: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29314242/co-morbidities-only-account-for-a-small-proportion-of-excess-mortality-after-fracture-a-record-linkage-study-of-individual-fracture-types
#3
Weiwen Chen, Judy M Simpson, Lyn M March, Fiona M Blyth, Dana Bliuc, Thach Tran, Tuan V Nguyen, John A Eisman, Jacqueline R Center
BACKGROUND: Non-hip non-vertebral fractures (NHNV) constitute the majority of osteoporotic fractures but few studies have examined the association between these fractures, co-morbidity and mortality. OBJECTIVE: To examine the relationship between individual non-hip non-vertebral fractures, co-morbidities and mortality. METHODS: Prospective population-based cohort of 267,043 subjects (45 and Up Study, Australia) had baseline questionnaires linked to hospital administrative and all-cause mortality data from 2006 - 2013...
January 4, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29306575/mouse-models-of-cancer-associated-thrombosis
#4
Yohei Hisada, Nigel Mackman
Cancer patients have an increased risk of venous thromboembolism (VTE) compared with the general population. Mouse models are used to better understand the mechanisms of cancer-associated thrombosis. Several mouse models of cancer-associated thrombosis have been developed that use different mouse strains, tumors, tumor sites and thrombosis models. In this review, we summarize these different models. These models have been used to determine the role of different pathways in cancer-associated thrombosis. For instance, they have revealed roles for tumor-derived tissue factor-positive microvesicles and neutrophil extracellular traps in thrombosis in tumor-bearing mice...
December 29, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/29296750/multiplexed-targeted-proteomic-assay-to-assess-coagulation-factor-concentrations-and-thrombosis-associated-cancer
#5
Yassene Mohammed, Bart J van Vlijmen, Juncong Yang, Andrew J Percy, Magnus Palmblad, Christoph H Borchers, Frits R Rosendaal
The plasma levels of pro- and anticoagulant proteins are important markers for venous thrombosis (VT) risk and can be affected by both genetic and acquired factors, including cancer. Generally, these markers are measured using activity- or antibody-based assays. Targeted proteomics with stable-isotope-labeled internal standards has proven adept at the rapid, multiplex, and precise quantification of proteins in complex biological samples such as plasma. We used liquid chromatography coupled to multiple reaction monitoring (MRM) mass spectrometry to evaluate the concentrations of 31 coagulation- and fibrinolysis-related proteins in plasma from 25 healthy controls, 25 patients with VT, and 25 patients with VT who were also diagnosed with cancer...
June 27, 2017: Blood Advances
https://www.readbyqxmd.com/read/29279692/long-term-survival-of-a-patient-with-adenocarcinoma-of-the-esophagogastric-junction-with-a-portal-vein-tumor-thrombosis-who-underwent-palliative-total-gastrectomy-a-case-report
#6
Sung Don Oh, Sung Jin Oh, Byoung Jo Suh, Jin Yong Shin, Jong Kwon Park
Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data. Herein, we report a case of PVTT associated with an adenocarcinoma of the esophagogastric junction that was successfully controlled by means of a palliative total gastrectomy without surgical resection of the PVTT and administration of palliative continuous doxifluridine.
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29279522/comparison-of-direct-oral-anticoagulants-and-warfarin-in-the-treatment-of-deep-venous-thrombosis-in-the-chronic-phase
#7
Shingo Wakakura, Fumihiko Hara, Tadashi Fujino, Asami Hamai, Hiroshi Ohara, Takayuki Kabuki, Masahiko Harada, Takanori Ikeda
We assessed the efficacy and safety of direct oral anticoagulants (DOACs) for the treatment of deep venous thrombosis (DVT) in the chronic phase through comparison with conventional warfarin therapy.A total of 807 consecutive patients who were diagnosed with having DVT in the chronic phase were included (484 patients to warfarin therapy and 323 patients to DOAC therapy). The condition of leg veins was assessed 3 to 6 months after starting the therapies by ultrasound examination. Major bleeding and mortality during the therapies were followed-up...
December 27, 2017: International Heart Journal
https://www.readbyqxmd.com/read/29278886/combination-of-preoperative-d-dimer-and-mean-platelet-volume-predicts-postoperative-deep-venous-thrombosis-in-breast-cancer-patients
#8
Li-Na Cui, Na Li, Shuang Fu, Xin Zhang, Xin Wang, Rui-Tao Wang
BACKGROUND: Deep venous thrombosis (DVT) is associated with severe morbidity and mortality in cancer. Mean platelet volume (MPV) is an indicator of activated platelets. OBJECTIVE: We aimed to investigate whether the combination of D-dimer and MPV could have a better performance in predicting deep venous thrombosis (DVT) in patients with breast cancer. MEHTODS: In 342 consecutive breast cancer patients without preoperative DVT, we measured the preoperative D-dimer and MPV levels...
December 15, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29274307/vitamin-k-antagonists-after-6-months-of-low-molecular-weight-heparin-in-cancer-patients-with-venous-thromboembolism
#9
Chatree Chai-Adisaksopha, Alfonso Iorio, Mark A Crowther, Javier de Miguel, Estuardo Salgado, Marija Zdraveska, Carmen Fernández-Capitán, José Antonio Nieto, Giovanni Barillari, Laurent Bertoletti, Manuel Monreal
BACKGROUND: Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromboembolism. However, data on continuing LMWH treatment beyond six months remain scanty. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the rate of venous thromboemblism recurrences and major bleeding appearing beyond the first 6 months of anticoagulant therapy in cancer patients with venous thromboemblism, according to therapy with LMWH or vitamin K antagonists (VKA)...
December 20, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/29249864/malignant-venous-obstruction-superior-vena-cava-syndrome-and-beyond
#10
REVIEW
Tamir Friedman, Keith B Quencer, Sirish A Kishore, Ronald S Winokur, David C Madoff
Venous obstruction in the cancer population can result in substantial morbidity and, in extreme cases, mortality. While venous obstruction can be caused by both benign and malignant etiologies in this population, the management of malignant venous obstruction as a palliative measure can be somewhat nuanced with respect to nonprocedural and procedural management, both with respect to treatment of the underlying malignancy as well as treatment of venous hypertension, which may be associated with venous thrombosis...
December 2017: Seminars in Interventional Radiology
https://www.readbyqxmd.com/read/29247594/genes-associated-with-venous-thromboembolism-in-colorectal-cancer-patients
#11
Betül Ünlü, Nick van Es, Wibowo Arindrarto, Szymon M Kiełbasa, Hailiang Mei, Johan Westerga, Saskia Middeldorp, Peter J K Kuppen, Hans-Martin Otten, Suzanne Cannegieter, Henri H Versteeg
BACKGROUND: Venous thromboembolism (VTE) is a frequent complication in patients with cancer and is associated with significant morbidity and mortality. However, the mechanisms behind cancer-associated thrombosis are still incompletely understood. OBJECTIVES: The aim is to identify novel genes that associate with VTE in patients with colorectal cancer (CRC). METHODS: Twelve CRC patients with VTE were age- and sex-matched to twelve CRC patients without VTE...
December 16, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/29245061/risk-and-prognosis-of-cancer-after-upper-extremity-deep-venous-thrombosis-a-population-based-cohort-study
#12
Kasper Adelborg, Erzsébet Horváth-Puhó, Jens Sundbøll, Paolo Prandoni, Anne Ording, Henrik Toft Sørensen
INTRODUCTION: The association between lower-extremity venous thrombosis and cancer is well-established. However, the extent to which upper-extremity deep venous thrombosis (U-DVT) is a marker of cancer and a prognostic factor for all-cause mortality remains poorly understood. We examined the risk of cancer after a diagnosis of U-DVT compared with cancer risk in the general population. MATERIALS AND METHODS: Using Danish nationwide population-based medical registries, we identified all patients with first-time U-DVT during 1980-1993 and 2000-2013...
November 22, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/29241089/association-of-psychosis-with-antiphospholipid-antibody-syndrome-a-systematic-review-of-clinical-studies
#13
Asma Hallab, Sadiq Naveed, Ahmed Altibi, Mariam Abdelkhalek, Huyen Thi Ngo, Thao Phuong Le, Kenji Hirayama, Nguyen Tien Huy
OBJECTIVE: In this systematic review, we reviewed the association between Antiphospholipid antibody syndrome (APS) and psychosis and focused on the prevalence, clinical presentation, immunologic and neurological workup, treatment options, and clinical outcomes. METHODOLOGY: We performed this systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)'s guidelines. We searched eight databases for potential articles and manually searched references and relevant articles of included studies...
November 16, 2017: General Hospital Psychiatry
https://www.readbyqxmd.com/read/29228619/fibrin-bearing-microparticles-marker-of-thrombo-embolic-events-in-pancreatic-and-colorectal-cancers
#14
Diane Mege, Lydie Crescence, Mehdi Ouaissi, Igor Sielezneff, Regis Guieu, Françoise Dignat-George, Christophe Dubois, Laurence Panicot-Dubois
Background: Microparticles (MPs) are plasma membrane-derived extracellular vesicles present in the bloodstream. We have described a specific signature of MPs, called microparticulosome, in colorectal (CRC) and pancreatic (PC) cancers. We observed that levels of fibrin-bearing MPs were significantly increased in patients suffering from PC and CRC in comparison with control groups. Here, we hypothesised that fibrin-MPs may constitute a relevant biomarker of thrombosis associated with cancer...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29222260/should-we-diagnose-and-treat-distal-deep-vein-thrombosis
#15
REVIEW
Helia Robert-Ebadi, Marc Righini
Ultrasound series report that isolated distal deep vein thrombosis (DVT), also known as calf DVT, represents up to 50% of all lower-limb DVTs and, therefore, is a frequent medical condition. Unlike proximal DVT and pulmonary embolism, which have been studied extensively and for which management is well standardized, much less is known about the optimal management of isolated calf DVT. Recent data arising from registries and nonrandomized studies have suggested that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222247/when-can-we-stop-anticoagulation-in-patients-with-cancer-associated-thrombosis
#16
REVIEW
Agnes Y Y Lee
The optimal duration of anticoagulant therapy in patients with cancer-associated venous thromboembolism (VTE) is unknown. Without well-designed studies evaluating the efficacy, safety, and cost-effectiveness of continuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recommendations are lacking. Consensus guidelines generally suggest continuing anticoagulation treatment in patients with active cancer or receiving cancer treatment, with periodic reassessment of the risks and benefits...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29212805/when-can-we-stop-anticoagulation-in-patients-with-cancer-associated-thrombosis
#17
Agnes Y Y Lee
The optimal duration of anticoagulation in patients with cancer-associated venous thromboembolism (VTE) is unknown. Without well-designed studies evaluating the efficacy, safety and cost-effectiveness of continuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recommendations are lacking. Consensus guidelines generally suggest continuing anticoagulation in patients with active cancer or receiving cancer treatment, with periodic reassessment of the risks and benefits...
December 6, 2017: Blood
https://www.readbyqxmd.com/read/29207321/a-multi-institutional-registry-of-pediatric-hospital-acquired-thrombosis-cases-the-children-s-hospital-acquired-thrombosis-chat-project
#18
Julie Jaffray, Arash Mahajerin, Guy Young, Neil Goldenberg, Lingyun Ji, Richard Sposto, Amy Stillings, Emily Krava, Brian Branchford
BACKGROUND: Pediatric hospital-acquired venous thromboembolism (HA-VTE) rates have increased dramatically. To achieve generalizable knowledge in the derivation and validation of HA-VTE risk factors and risk prediction models and inform future risk-stratified prevention strategies, multi-institutional studies are needed. OBJECTIVES: This paper presents an investigator-initiated, multicenter pediatric case-cohort study designed to identify risk factors for HA-VTE to create a HA-VTE risk prediction model...
December 1, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/29206177/new-therapeutic-agent-against-arterial-thrombosis-an-iridium-iii-derived-organometallic-compound
#19
Chih-Wei Hsia, Marappan Velusamy, Jeng-Ting Tsao, Chih-Hsuan Hsia, Duen-Suey Chou, Thanasekaran Jayakumar, Lin-Wen Lee, Jiun-Yi Li, Joen-Rong Sheu
Platelet activation plays a major role in cardio and cerebrovascular diseases, and cancer progression. Disruption of platelet activation represents an attractive therapeutic target for reducing the bidirectional cross talk between platelets and tumor cells. Platinum (Pt) compounds have been used for treating cancer. Hence, replacing Pt with iridium (Ir) is considered a potential alternative. We recently developed an Ir(III)-derived complex, [Ir(Cp*)1-(2-pyridyl)-3-(2-hydroxyphenyl)imidazo[1,5-a]pyridine Cl]BF₄ (Ir-11), which exhibited strong antiplatelet activity; hence, we assessed the therapeutic potential of Ir-11 against arterial thrombosis...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29203044/-new-international-guidelines-for-curative-treatment-and-prophylaxis-for-venous-thromboembolism-vte-in-cancer-patients-and-the-dedicated-smartphone-application
#20
I Benzidia, J Connault, A Solanilla, U Michon-Pasturel, M Jamelot, M K Nguessan, A Hij, C Le Maignan, D Farge, C Frère
Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients, and the second leading cause of death in this setting. Cancer patients are also more likely to present recurrent VTE and major bleeding while taking anticoagulants. Management of VTE in these patients is always challenging and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME) released international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis, based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale...
December 2017: Journal de Médecine Vasculaire
keyword
keyword
120640
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"